Verily, the life sciences arm of Alphabet, raises $1B in round led by Silver Lake, says Alphabet CFO Ruth Porat and Silver Lake's Egon Durban are joining board
- Alphabet's Verily is raising $1 billion in a new round led by Silver Lake, and Ruth Porat is joining the board.
Context & Ripple Effects
Verily has been building a track record of raising outside capital against Alphabet's ownership: Temasek's $800M investment in 2017 bought the Singaporean firm a minority stake and an operating-board seat, and this Silver Lake–led $1B round extends that playbook with two marquee board additions — Alphabet CFO Ruth Porat and Silver Lake's Egon Durban.
The raise lands just months before Verily moves into clinical trials via partnerships with Novartis, Sanofi, Otsuka, and Pfizer, so the new capital arrives as the company shifts from research projects toward commercial businesses.
First-order effects
- Verily banks $1B led by Silver Lake, whose Egon Durban now sits on its board alongside Ruth Porat — giving the life sciences unit direct private-equity governance input for the first time in its funding history.
Second-order effects
- Each successive round — Temasek in 2017, Silver Lake here, then an Alphabet-led $1B in 2022 — trades Alphabet control for fresh capital, a dilution path that ends with the $300M Series X round where Alphabet remains an investor but no longer holds a controlling stake.
Third-order effects
- If the pattern holds, Alphabet's moonshot divisions become quasi-independent companies financed on their own balance sheets, with the parent's role shrinking from owner to anchor investor as commercialization timelines stretch past what internal funding will carry.
The trend: Alphabet is progressively externalizing its other-bets divisions through serial private rounds that dilute parent control while importing outside investors' governance.